Nautilus Biotechnology Reports Q2 GAAP EPS of -$0.11, Beats Estimates
Nautilus Biotechnology (NASDAQ: NAUT) reported second-quarter financial results with a GAAP earnings per share (EPS) loss of $0.11, which exceeded expectations by $0.03. Revenue for the quarter was $0.19 million, driven primarily by grant revenue from The Michael J. Fox Foundation and service revenue from its Iterative Mapping Early Access Program. The company's stock rose 3% post-market following the earnings release. Despite a loss, Nautilus managed to outperform estimates in both EPS and revenue, signaling some positive momentum for the biotech firm as it continues to develop its genomic sequencing platform. This performance highlights early progress from grant-funded activities and initial service offerings, though significant financial challenges remain due to ongoing R&D costs.
Tickers: $NAUT
Topics: biotech eps financials revenue